GHAPP PBC Podcast Series Part 3: The Key Highlights of PBC at the GHAPP Conference 2024

Welcome back to the final installment of our three-part miniseries on Primary Biliary Cholangitis (PBC) from the GHAPP National 2024 Conference! In this episode, Elizabeth Goacher, FNP, Jeremy Davis, NP, and Allison Moser, NP discuss the most impactful updates in PBC management, treatment goals, and evolving clinical strategies.

A major highlight from this year’s meeting is the shifting treatment paradigm in PBC, moving beyond traditional Poise criteria to a more aggressive target of achieving completely normal alkaline phosphatase (ALKP) levels and a bilirubin of ≤0.6. Experts emphasize that new therapies, including seladelpar and elafibranor, are helping clinicians push treatment goals further, optimizing patient outcomes and disease management.

With the PBC treatment landscape evolving, the panel discusses how the mindset around ALKP reduction has changed, underscoring the importance of setting normalization as the primary goal rather than just achieving a modest reduction. With new and emerging therapies, there is growing excitement about more effective disease control and improved long-term prognosis for patients with PBC.

Watch now to stay ahead on the latest PBC treatment advancements, and don’t forget to check out the full miniseries! For more resources, visit GHAPP.org or download the GHAPP ACE app.